SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3759)2/26/2004 3:18:14 PM
From: scaram(o)ucheRead Replies (1) | Respond to of 4974
 
As always, there's the question......

differential in market cap between the haves and the have nots? does the market cap of a Genentech come back hard, or does it put downside cushion to the wannabe(')s?

the sector is going to thrive. it's going strong. the last 12 months are right out of a biofreak's dream.

Here's hoping that threadsters are the better for it.



To: scaram(o)uche who wrote (3759)2/26/2004 5:48:27 PM
From: Miljenko ZuanicRead Replies (1) | Respond to of 4974
 
Bravo, bravo, bravo Genentech!

<<Food and Drug Administration (FDA) has approved Avastin(TM) (bevacizumab) to be used in combination with intravenous 5-Fluorouracil-based chemotherapy as a treatment for patients with first-line --or previously untreated -- metastatic cancer of the colon or rectum.>>

We do not know (yet) wording in label, but this is different than IFL label! Very strong implication for future!

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News